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ABSTRACT i 
At present, a skeletal muscle biopsy provides the most specific 
test for susceptibility to Malignant Hyperthermia (MH). This procedure 
is unsuitable for large scale screening of individuals and a simpler, 
less invasive test to distinguish MR-susceptible (MHS) people from 
those not possessing the genetic defect, is highly desirable. 
Platelets contain a calcium-activated contractile system, a 
calcium-storing and releasing system, and an active ATP-generating 
system. It is thus logical to assume that the same processes occur in 
platelets as those in muscle during MR-induced accelerated metabolism. 
In this research, [8- 14c]adenine incorporation into blood platelet 
adenine nucleotides was investigated with a view to using differences 
between platelets from normal and MHS individuals as the basis for a 
clinical test. 
It was assumed that under resting and/or halothane-stimulated 
conditions, nucleotide turnover in MHS platelets is significantly 
abnormal, and that the turnover abnormality is reflected in differences 
in adenine incorporation to platelet nucleotides via the salvage 
pathway. 
MHS platelets took up less adenine and assimilated it into 
nucleotides at a slower rate than normal platelets. However, after two 
hours, 20% more labelled ATP was extracted from MHS platelets than 
normal, with a concomittant decrease in ADP levels. Halothane had 
little effect on normal platelets but caused a 10% decrease in 
incorporation into ATP in MHS platelets. AMP labelling was lower than 
normal in MHS platelets, indicating increased deamination of this 
ABSTRACT ii 
nucleotide. 
Specific radioactivities of nucleotides were not measured since 
[ 14c]adenine distributes evenly among metabolic ATP, ADP, and AMP; 
therefore, the total radioactivities were used as a measure for the 
levels of adenine nucleotides within the metabolic pool. 
From the limited number of individuals screened, results suggest 
that MHS platelets have a higher basal ATP turnover rate than normal. 
When challenged with halothane the adenylate energy charge decreased, 
causing an increased nucleotide turnover rate which in turn led to a 
decreased ATP level due to the increased deamination of AMP. The 
appearance of more hypoxanthine and inosine than normal in the 
extraplatelet medium is consistent with the above sequence of events. 
The platelet-halothane bioassay displays a limited ability to 
distinguish between normal and MHS individuals and may have the 
potential to become a less invasive equivalent to the "ATP-depletion 
test" in muscle. 
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